miR-200bc/429 Inhibits Osteosarcoma Cell Proliferation and Invasion by Targeting PMP22

Abstract

BackgroundMicroRNAs (miRNAs) are small non-coding RNAs which play a crucial role in diverse biological processes and could contribute to cancer development and progression. MiR-200bc/429 have been found to be aberrantly expressed in osteosarcoma (OS). However, the features of miR-200bc/429 in the tumorigenesis and progress of OS remain poorly understood.Material/MethodsThe miR-200bc/429 expression was firstly identified in human OS clinical samples and cell lines by quantitative real-time PCR (qRT-PCR). After transfection with miR-200bc/429 mimics or negative control in U2OS or MG63 cells, cell proliferation was measured by CCK-8 assay. Following that, wound-healing assay and Transwell invasion assay were performed to evaluate cell migration and invasion, respectively. Finally, luciferase reporter assay and Western blot analysis were performed to determine if peripheral myelin protein-22 (PMP22) is a direct target of miR-200bc/429.ResultsResults revealed that miR-200bc/429 were significantly depressed in human OS tissues and cell lines by qRT-PCR. Then, restoration of miR-200bc/429 significantly inhibited cell proliferation (P<0.05) and invasion (P<0.05) in vitro. Luciferase reporter assay and Western blot analysis revealed that miR-200bc/429 could directly target PMP22 3′ untranslated region (UTR) and inhibit its expression in U2OS and MG63 cells.ConclusionsThese findings suggest that miR-200bc/429 inhibit OS cells proliferation and invasion by targeting PMP22, and function as a tumor suppressor and may be a patent molecular marker as well as a potential target for OS therapy.

Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway

“…Osteosarcoma is one of the most prevalent types of bone tumors, mainly detected in adolescents and children. It has been reported that around 70% of osteosarcoma patients are ages 10–25 years [ 1 ]. The development of chemoresistance among osteosarcoma patients forms a bottleneck in the treatment of osteosarcoma [ 2 ].…”

Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells

“…OS typically presents between the ages of 10 and 20 years or in elderly patients (2,3) and generally develops from primitive mesenchymal bone-forming cells in the long bones (4). At present, the therapeutic options for OS are surgery and intensive multi-agent chemotherapy, including cisplatin, doxorubicin, ifosfamide and methotrexate (5). The 5-year survival rate of patients with OS without metastases is 60-70%, depending on the use of chemotherapy (6).…”

Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers

“…The PMP22 protein regulates cell growth cycle, cell adhesion, and apoptosis, and is irregularly expressed in various malignant tumors. Its overexpression is associated with the occurrence and progression of lung cancer, breast cancer, gastric cancer, pancreatic cancer, and osteosarcoma [ 39 , 40 ]. Hence, PMP22 might have a great value in the clinical treatment and prognosis of malignant tumors.…”